Compare Dow Jones Industrial Average ETF (DIA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Novartis AG — how do they compare? Dow Jones Industrial Average ETF trades at $516.4 (market cap $45.20B), while Novartis AG trades at $143.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 5.9× Dow Jones Industrial Average ETF's market cap, and Novartis AG pays a 3.31% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Novartis AG for 82 Days on average.
| DIA | NVS | |
|---|---|---|
Market Cap | $45.20B | $268.57B |
Volume | 4,095,368 | 1,532,573 |
52-Week High | $542.79 | $168.62 |
52-Week Low | $451.37 | $121.80 |
Typical Hold Time | 104 Days | 82 Days |
Sector | — | Health |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $515.82, up 0.94% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 46.24, while recent dividend distributions provide income appeal. Support levels cluster around $507-510 with resistance at $513-516.
Market sentiment reflects cautious optimism amid economic uncertainty, with institutional focus on Fed policy and earnings resilience. Key risks include interest rate sensitivity and market volatility, though the ETF's diversified Dow Jones exposure offers defensive characteristics in turbulent markets.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
